西妥昔单抗
医学
卡铂
内科学
肿瘤科
紫杉烷
不利影响
氟尿嘧啶
头颈部癌
头颈部鳞状细胞癌
临床试验
放射治疗
化疗
顺铂
癌症
结直肠癌
乳腺癌
作者
Christophe Le Tourneau,M. Ghiani,Maria Chiara Cau,Roberta Depenni,Graziana Ronzino,Pierluigi Bonomo,Vincenzo Montesarchio,Luigi Leo,Jeltje Schulten,Satu Salmio,Diethelm Messinger,Andrea Sbrana,Édith Borcoman,Maria Grazia Ghi
摘要
ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).This multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes.Previously untreated patients with R/M SCCHN whose planned treatment was cetuximab plus PBT were enrolled from 6 countries. Among 221 evaluable patients, planned treatments included cetuximab plus carboplatin (31.2%), cisplatin plus 5-fluorouracil (31.7%), or carboplatin plus 5-fluorouracil (23.1%); 3.2% included a taxane, and 45.2% did not include 5-fluorouracil. Cetuximab treatment was planned for a fixed duration (≤24 weeks) in 15 patients (6.8%) and until disease progression in 206 (93.2%). Median progression-free survival and overall survival were 6.5 and 10.8 months, respectively. Grade ≥3 adverse events occurred in 39.8% of patients. Serious adverse events occurred in 25.8% of patients; 5.4% were cetuximab-related.In patients with R/M SCCHN, first-line cetuximab plus PBT was feasible and modifiable in a real-world setting with similar toxicity and efficacy as in the pivotal phase III EXTREME trial.EMR 062202-566.
科研通智能强力驱动
Strongly Powered by AbleSci AI